

Marcel M Verbeek

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9400669/publications.pdf>

Version: 2024-02-01

278
papers

16,608
citations

13099

68
h-index

19190

118
g-index

326
all docs

326
docs citations

326
times ranked

18643
citing authors

#	ARTICLE	IF	CITATIONS
1	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. JAMA - Journal of the American Medical Association, 2015, 313, 1924.	7.4	1,166
2	CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment. JAMA - Journal of the American Medical Association, 2009, 302, 385.	7.4	1,009
3	Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurology, The, 2009, 8, 619-627.	10.2	542
4	Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology. JAMA Neurology, 2019, 76, 1035.	9.0	455
5	Glucose transporter-1 deficiency syndrome: the expanding clinical and genetic spectrum of a treatable disorder. Brain, 2010, 133, 655-670.	7.6	356
6	The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimer's and Dementia, 2011, 7, 386.	0.8	354
7	A Practical Guide to Immunoassay Method Validation. Frontiers in Neurology, 2015, 6, 179.	2.4	348
8	CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimer's and Dementia, 2013, 9, 251-261.	0.8	344
9	Effect of 1 Night of Total Sleep Deprivation on Cerebrospinal Fluid β -Amyloid 42 in Healthy Middle-Aged Men. JAMA Neurology, 2014, 71, 971.	9.0	320
10	Prognosis of coma after therapeutic hypothermia: A prospective cohort study. Annals of Neurology, 2012, 71, 206-212.	5.3	290
11	Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. Biomarkers in Medicine, 2012, 6, 419-430.	1.4	280
12	Tyrosine hydroxylase deficiency: a treatable disorder of brain catecholamine biosynthesis. Brain, 2010, 133, 1810-1822.	7.6	268
13	MicroRNAs in Alzheimer's disease: differential expression in hippocampus and cell-free cerebrospinal fluid. Neurobiology of Aging, 2014, 35, 152-158.	3.1	220
14	Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. World Journal of Biological Psychiatry, 2018, 19, 244-328.	2.6	215
15	Autoantibodies to cytosolic 5'-nucleotidase 1A in inclusion body myositis. Annals of Neurology, 2013, 73, 397-407.	5.3	206
16	Small heat shock proteins inhibit amyloid- β protein aggregation and cerebrovascular amyloid- β protein toxicity. Brain Research, 2006, 1089, 67-78.	2.2	193
17	Heparan sulphate proteoglycans in Alzheimer's disease and amyloid-related disorders. Lancet Neurology, The, 2003, 2, 482-492.	10.2	192
18	Cerebral Microvascular Amyloid β Protein Deposition Induces Vascular Degeneration and Neuroinflammation in Transgenic Mice Expressing Human Vasculotropic Mutant Amyloid β Precursor Protein. American Journal of Pathology, 2005, 167, 505-515.	3.8	177

#	ARTICLE	IF	CITATIONS
19	Consensus guideline for the diagnosis and treatment of aromatic l-amino acid decarboxylase (AADC) deficiency. <i>Orphanet Journal of Rare Diseases</i> , 2017, 12, 12.	2.7	172
20	Cerebrospinal fluid amyloid β is decreased in cerebral amyloid angiopathy. <i>Annals of Neurology</i> , 2009, 66, 245-249.	5.3	171
21	The increasing impact of cerebral amyloid angiopathy: essential new insights for clinical practice. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 982-994.	1.9	162
22	Impact of molecular imaging on the diagnostic process in a memory clinic. <i>Alzheimer's and Dementia</i> , 2013, 9, 414-421.	0.8	159
23	Age and diagnostic performance of Alzheimer disease CSF biomarkers. <i>Neurology</i> , 2012, 78, 468-476.	1.1	154
24	Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis. <i>Neurology</i> , 2018, 90, e22-e30.	1.1	148
25	Rapid Degeneration of Cultured Human Brain Pericytes by Amyloid β Protein. <i>Journal of Neurochemistry</i> , 1997, 68, 1135-1141.	3.9	144
26	Pathogenesis of cerebral amyloid angiopathy. <i>Brain Research Reviews</i> , 2003, 43, 207-223.	9.0	142
27	Association of Cerebral Amyloid- β Aggregation With Cognitive Functioning in Persons Without Dementia. <i>JAMA Psychiatry</i> , 2018, 75, 84.	11.0	133
28	Small heat shock protein HspB8: its distribution in Alzheimer's disease brains and its inhibition of amyloid- β protein aggregation and cerebrovascular amyloid- β toxicity. <i>Acta Neuropathologica</i> , 2006, 111, 139-149.	7.7	125
29	Agrin Is a Major Heparan Sulfate Proteoglycan Accumulating in Alzheimer's Disease Brain. <i>American Journal of Pathology</i> , 1999, 155, 2115-2125.	3.8	123
30	No Effect of One-Year Treatment with Indomethacin on Alzheimer's Disease Progression: A Randomized Controlled Trial. <i>PLoS ONE</i> , 2008, 3, e1475.	2.5	123
31	CSF neurofilament light chain and tau differentiate multiple system atrophy from Parkinson's disease. <i>Neurobiology of Aging</i> , 2007, 28, 742-747.	3.1	121
32	Lipoprotein Receptor-Related Protein-1 Mediates Amyloid- β -Mediated Cell Death of Cerebrovascular Cells. <i>American Journal of Pathology</i> , 2007, 171, 1989-1999.	3.8	120
33	MicroRNA-29a Is a Candidate Biomarker for Alzheimer's Disease in Cell-Free Cerebrospinal Fluid. <i>Molecular Neurobiology</i> , 2016, 53, 2894-2899.	4.0	120
34	MicroRNAs in Cerebrospinal Fluid as Potential Biomarkers for Parkinson's Disease and Multiple System Atrophy. <i>Molecular Neurobiology</i> , 2017, 54, 7736-7745.	4.0	119
35	Disease specificity of autoantibodies to cytosolic 5'-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 696-701.	0.9	116
36	Cerebrospinal Fluid Glucose and Lactate: Age-Specific Reference Values and Implications for Clinical Practice. <i>PLoS ONE</i> , 2012, 7, e42745.	2.5	109

#	ARTICLE	IF	CITATIONS
37	Cerebrospinal Fluid Analysis in the Workup of GLUT1 Deficiency Syndrome. <i>JAMA Neurology</i> , 2013, 70, 1440.	9.0	106
38	Heat Shock Proteins and Amateur Chaperones in Amyloid-Beta Accumulation and Clearance in Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2007, 35, 203-216.	4.0	105
39	Inhibition of α -synuclein aggregation by small heat shock proteins. <i>Proteins: Structure, Function and Bioinformatics</i> , 2011, 79, 2956-2967.	2.6	104
40	Amyloid- β oligomer detection by ELISA in cerebrospinal fluid and brain tissue. <i>Analytical Biochemistry</i> , 2013, 433, 112-120.	2.4	103
41	Serum NFL discriminates Parkinson disease from atypical parkinsonisms. <i>Neurology</i> , 2019, 92, e1479-e1486.	1.1	100
42	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. <i>JAMA Neurology</i> , 2022, 79, 228.	9.0	97
43	Reciprocal interactions between sleep, circadian rhythms and Alzheimer's disease: Focus on the role of hypocretin and melatonin. <i>Ageing Research Reviews</i> , 2013, 12, 188-200.	10.9	95
44	α -Synuclein real-time quaking-induced conversion in the cerebrospinal fluid of uncertain cases of parkinsonism. <i>Annals of Neurology</i> , 2019, 85, 777-781.	5.3	94
45	Heparan sulfate proteoglycan expression in cerebrovascular amyloid β deposits in Alzheimer's disease and hereditary cerebral hemorrhage with amyloidosis (Dutch) brains. <i>Acta Neuropathologica</i> , 2001, 102, 604-614.	7.7	93
46	Anxiety is related to Alzheimer cerebrospinal fluid markers in subjects with mild cognitive impairment. <i>Psychological Medicine</i> , 2013, 43, 911-920.	4.5	93
47	Prevalence of cerebral amyloid angiopathy: A systematic review and meta-analysis. <i>Alzheimer's and Dementia</i> , 2022, 18, 10-28.	0.8	93
48	Cerebrospinal Fluid Amyloid ss42/Phosphorylated Tau Ratio Discriminates Between Alzheimer's Disease and Vascular Dementia. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2006, 61, 755-758.	3.6	89
49	CSF α -synuclein does not differentiate between parkinsonian disorders. <i>Neurobiology of Aging</i> , 2012, 33, 430.e1-430.e3.	3.1	89
50	LRP1 shedding in human brain: roles of ADAM10 and ADAM17. <i>Molecular Neurodegeneration</i> , 2009, 4, 17.	10.8	88
51	Cerebrospinal fluid analysis differentiates multiple system atrophy from Parkinson's disease. <i>Movement Disorders</i> , 2004, 19, 571-579.	3.9	87
52	Expression pattern of apoptosis-related markers in Huntington's disease. <i>Acta Neuropathologica</i> , 2005, 109, 321-328.	7.7	87
53	Cerebrospinal Fluid α -Synuclein Does Not Discriminate Between Dementia Disorders. <i>Journal of Alzheimer's Disease</i> , 2009, 16, 363-369.	2.6	87
54	CSF α -Synuclein Does Not Discriminate Dementia with Lewy Bodies from Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2010, 22, 87-95.	2.6	87

#	ARTICLE	IF	CITATIONS
55	The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review. <i>Alzheimer's and Dementia</i> , 2018, 14, 1313-1333.	0.8	87
56	Neurofilament ELISA validation. <i>Journal of Immunological Methods</i> , 2010, 352, 23-31.	1.4	86
57	The utility of β -synuclein as biofluid marker in neurodegenerative diseases: a systematic review of the literature. <i>Biomarkers in Medicine</i> , 2016, 10, 19-34.	1.4	86
58	Consensus guideline for the diagnosis and treatment of tetrahydrobiopterin (BH4) deficiencies. <i>Orphanet Journal of Rare Diseases</i> , 2020, 15, 126.	2.7	85
59	Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study. <i>Alzheimer's and Dementia</i> , 2019, 15, 742-753.	0.8	82
60	Cerebral tryptophan metabolism and outcome of tuberculous meningitis: an observational cohort study. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 526-535.	9.1	77
61	MALDI-TOF Mass Spectrometry Analysis of Cerebrospinal Fluid Tryptic Peptide Profiles to Diagnose Leptomeningeal Metastases in Patients with Breast Cancer. <i>Molecular and Cellular Proteomics</i> , 2005, 4, 1341-1349.	3.8	76
62	Current state and future directions of neurochemical biomarkers for Alzheimer's disease. <i>Clinical Chemistry and Laboratory Medicine</i> , 2007, 45, 1421-34.	2.3	76
63	Reference measurement procedures for Alzheimer's disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid β 42. <i>Biomarkers in Medicine</i> , 2012, 6, 409-417.	1.4	76
64	Structural biomarkers in the cerebrospinal fluid within 24h after a traumatic spinal cord injury: a descriptive analysis of 16 subjects. <i>Spinal Cord</i> , 2014, 52, 428-433.	1.9	74
65	Plasma β 2 amyloid and the risk of Alzheimer's disease in Down syndrome. <i>Neurobiology of Aging</i> , 2012, 33, 1988-1994.	3.1	73
66	CSF neurofilament protein analysis in the differential diagnosis of ALS. <i>Journal of Neurology</i> , 2009, 256, 615-619.	3.6	72
67	Variability of CSF Alzheimer's Disease Biomarkers: Implications for Clinical Practice. <i>PLoS ONE</i> , 2014, 9, e100784.	2.5	72
68	Fluid biomarkers in multiple system atrophy: A review of the MSA Biomarker Initiative. <i>Neurobiology of Disease</i> , 2015, 80, 29-41.	4.4	71
69	CSF levels of DJ-1 and tau distinguish MSA patients from PD patients and controls. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 112-115.	2.2	70
70	Collagen XVIII: a Novel Heparan Sulfate Proteoglycan Associated with Vascular Amyloid Depositions and Senile Plaques in Alzheimer's Disease Brains. <i>Brain Pathology</i> , 2002, 12, 456-462.	4.1	69
71	Amyloid Beta Protein and Tau in Cerebrospinal Fluid and Plasma as Biomarkers for Dementia: A Review of Recent Literature. <i>Current Clinical Pharmacology</i> , 2008, 3, 123-131.	0.6	68
72	GLUT1 deficiency syndrome into adulthood: a follow-up study. <i>Journal of Neurology</i> , 2014, 261, 589-599.	3.6	67

#	ARTICLE	IF	CITATIONS
73	TDP-43 plasma levels are higher in amyotrophic lateral sclerosis. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 2012, 13, 446-451.	2.1	66
74	Enoxaparin treatment administered at both early and late stages of amyloid β deposition improves cognition of APP ^{swe} /PS1 ^{dE9} mice with differential effects on brain $A\beta$ levels. <i>Neurobiology of Disease</i> , 2010, 40, 340-347.	4.4	65
75	Accumulation of heparan sulfate proteoglycans in cerebellar senile plaques. <i>Neurobiology of Aging</i> , 2002, 23, 537-545.	3.1	64
76	Insulin inhibits amyloid β -induced cell death in cultured human brain pericytes. <i>Neurobiology of Aging</i> , 2004, 25, 93-103.	3.1	64
77	Microglial Upregulation of Progranulin as a Marker of Motor Neuron Degeneration. <i>Journal of Neuropathology and Experimental Neurology</i> , 2010, 69, 1191-1200.	1.7	64
78	Endotoxemia-induced inflammation and the effect on the human brain. <i>Critical Care</i> , 2010, 14, R81.	5.8	64
79	Measurement of glial fibrillary acidic protein in blood: an analytical method. <i>Clinica Chimica Acta</i> , 2002, 326, 151-154.	1.1	62
80	Quality Assurance for Cerebrospinal Fluid Protein Analysis: International Consensus by an Internet-Based Group Discussion. <i>Clinical Chemistry and Laboratory Medicine</i> , 2003, 41, 331-7.	2.3	62
81	Diagnostic Accuracy of ELISA and xMAP Technology for Analysis of Amyloid β 42 and Tau Proteins. <i>Clinical Chemistry</i> , 2007, 53, 859-865.	3.2	62
82	Methods for Analysis of Amyloid- β Aggregates. <i>Journal of Alzheimer's Disease</i> , 2012, 28, 735-758.	2.6	62
83	CSF Neurofilament Light Chain but not FLT3 Ligand Discriminates Parkinsonian Disorders. <i>Frontiers in Neurology</i> , 2015, 6, 91.	2.4	60
84	Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders. <i>Journal of Neurochemistry</i> , 2016, 139, 290-317.	3.9	58
85	β -Amyloid in CSF. <i>Neurology</i> , 2017, 88, 169-176.	1.1	58
86	Prevalence of the apolipoprotein E ϵ 4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 913-924.	0.8	58
87	Differences between the Pathogenesis of Senile Plaques and Congophilic Angiopathy in Alzheimer Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 1997, 56, 751-761.	1.7	57
88	Sulfation of heparan sulfate associated with amyloid- β plaques in patients with Alzheimer's disease. <i>Acta Neuropathologica</i> , 2010, 119, 211-220.	7.7	55
89	Association between Hypocretin-1 and Amyloid- β 42 Cerebrospinal Fluid Levels in Alzheimer's Disease and Healthy Controls. <i>Current Alzheimer Research</i> , 2012, 9, 1119-1125.	1.4	55
90	Apolipoprotein E Genotype Regulates Amyloid- β Cytotoxicity. <i>Journal of Neuroscience</i> , 2005, 25, 3621-3627.	3.6	52

#	ARTICLE	IF	CITATIONS
91	Amyloid- β^2 Oligomers Relate to Cognitive Decline in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 45, 35-43.	2.6	52
92	Limitations of the hCMEC/D3 cell line as a model for $A\beta^2$ clearance by the human blood-brain barrier. <i>Journal of Neuroscience Research</i> , 2017, 95, 1513-1522.	2.9	52
93	Inflammation biomarker discovery in Parkinson's disease and atypical parkinsonisms. <i>BMC Neurology</i> , 2020, 20, 26.	1.8	51
94	Movement disorders in GLUT1 deficiency syndrome respond to the modified Atkins diet. <i>Movement Disorders</i> , 2013, 28, 1439-1442.	3.9	47
95	C-Reactive Protein, Plasma Amyloid- β^2 Levels, and Their Interaction With Magnetic Resonance Imaging Markers. <i>Stroke</i> , 2018, 49, 2692-2698.	2.0	46
96	Apolipoprotein E protects cultured pericytes and astrocytes from D- $A\beta^21\beta^40$ -mediated cell death. <i>Brain Research</i> , 2010, 1315, 169-180.	2.2	45
97	CXCL16 is elevated in the cerebrospinal fluid versus serum and in inflammatory conditions with suspected and proved central nervous system involvement. <i>Neuroscience Letters</i> , 2006, 397, 145-148.	2.1	44
98	Susceptibility-Weighted Imaging Improves the Diagnostic Accuracy of 3T Brain MRI in the Work-Up of Parkinsonism. <i>American Journal of Neuroradiology</i> , 2015, 36, 454-460.	2.4	44
99	Validation of microRNAs in Cerebrospinal Fluid as Biomarkers for Different Forms of Dementia in a Multicenter Study. <i>Journal of Alzheimer's Disease</i> , 2016, 52, 1321-1333.	2.6	44
100	Human Prion Diseases in The Netherlands (1998-2009): Clinical, Genetic and Molecular Aspects. <i>PLoS ONE</i> , 2012, 7, e36333.	2.5	44
101	Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid. <i>Clinical Chemistry and Laboratory Medicine</i> , 2022, 60, 207-219.	2.3	44
102	Amyloid-beta-induced Degeneration of Human Brain Pericytes Is Dependent on the Apolipoprotein E Genotype. <i>Annals of the New York Academy of Sciences</i> , 2000, 903, 187-199.	3.8	43
103	Animal models of cerebral amyloid angiopathy. <i>Clinical Science</i> , 2017, 131, 2469-2488.	4.3	43
104	Plasma Amyloid- β^2 Levels, Cerebral Small Vessel Disease, and Cognition: The Rotterdam Study. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 977-987.	2.6	43
105	Cerebrovascular and amyloid pathology in prodementia stages: the relationship with neurodegeneration and cognitive decline. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 101.	6.2	43
106	Immunocapture-based fluorometric assay for the measurement of neprilysin-specific enzyme activity in brain tissue homogenates and cerebrospinal fluid. <i>Journal of Neuroscience Methods</i> , 2008, 167, 229-236.	2.5	41
107	Reviewing reasons for the decreased CSF A β 242 concentration in Alzheimer. <i>Frontiers in Bioscience - Landmark</i> , 2012, 17, 2024.	3.0	41
108	Tau Rather than TDP-43 Proteins are Potential Cerebrospinal Fluid Biomarkers for Frontotemporal Lobar Degeneration Subtypes: A Pilot Study. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 585-595.	2.6	41

#	ARTICLE	IF	CITATIONS
109	Regulator of oligodendrocyte maturation, miR-219, a potential biomarker for MS. <i>Journal of Neuroinflammation</i> , 2017, 14, 235.	7.2	41
110	Linking APOE- μ 4, blood-brain barrier dysfunction, and inflammation to Alzheimer's pathology. <i>Neurobiology of Aging</i> , 2020, 85, 96-103.	3.1	41
111	Expression of the cytokine leukemia inhibitory factor and pro-apoptotic insulin-like growth factor binding protein-3 in Alzheimer's disease. <i>Acta Neuropathologica</i> , 2002, 104, 525-533.	7.7	40
112	CSF d-serine concentrations are similar in Alzheimer's disease, other dementias, and elderly controls. <i>Neurobiology of Aging</i> , 2016, 42, 213-216.	3.1	40
113	White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 30.	6.2	40
114	Small heat shock proteins associated with cerebral amyloid angiopathy of hereditary cerebral hemorrhage with amyloidosis (Dutch type) induce interleukin-6 secretion. <i>Neurobiology of Aging</i> , 2009, 30, 229-240.	3.1	39
115	Plasma amyloid- β 2 levels, cerebral atrophy and risk of dementia: a population-based study. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 63.	6.2	39
116	CSF Neurofilament Proteins Levels are Elevated in Sporadic Creutzfeldt-Jakob Disease. <i>Journal of Alzheimer's Disease</i> , 2010, 21, 569-576.	2.6	38
117	Serum Neuron-Specific Enolase Levels from the Same Patients Differ Between Laboratories: Assessment of a Prospective Post-cardiac Arrest Cohort. <i>Neurocritical Care</i> , 2013, 19, 161-166.	2.4	38
118	Conventional 3T brain MRI and diffusion tensor imaging in the diagnostic workup of early stage parkinsonism. <i>Neuroradiology</i> , 2015, 57, 655-669.	2.2	38
119	CSF Tau, A β 242, and MHPG Differentiate Dementia with Lewy Bodies from Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2011, 27, 377-384.	2.6	36
120	Small Heat Shock Proteins Induce a Cerebral Inflammatory Reaction. <i>Journal of Neuroscience</i> , 2011, 31, 11992-12000.	3.6	36
121	Hourly variability of cerebrospinal fluid biomarkers in Alzheimer's disease subjects and healthy older volunteers. <i>Neurobiology of Aging</i> , 2012, 33, 831.e1-831.e9.	3.1	36
122	The Central Biobank and Virtual Biobank of BIOMARKAPD: A Resource for Studies on Neurodegenerative Diseases. <i>Frontiers in Neurology</i> , 2015, 6, 216.	2.4	36
123	Nigrosome-1 on Susceptibility Weighted Imaging to Differentiate Parkinson's Disease From Atypical Parkinsonism: An In Vivo and Ex Vivo Pilot Study. <i>Polski Przegląd Radiologii I Medycyny Nuklearnej</i> , 2016, 81, 363-369.	1.0	36
124	A de novo p.Asp18Asn mutation in <i>TREX1</i> in a patient with Aicardi-Goutières syndrome. <i>American Journal of Medical Genetics, Part A</i> , 2010, 152A, 2612-2617.	1.2	35
125	Has CXCL13 an Added Value in Diagnosis of Neurosyphilis?. <i>Journal of Clinical Microbiology</i> , 2015, 53, 1693-1696.	3.9	35
126	Ancillary investigations to diagnose parkinsonism: a prospective clinical study. <i>Journal of Neurology</i> , 2015, 262, 346-356.	3.6	34

#	ARTICLE	IF	CITATIONS
127	Cerebrospinal fluid A β levels in multiple system atrophy. <i>Movement Disorders</i> , 2004, 19, 238-240.	3.9	32
128	A more efficient enzyme-linked immunosorbent assay for measurement of β -synuclein in cerebrospinal fluid. <i>Journal of Neuroscience Methods</i> , 2008, 168, 182-185.	2.5	32
129	Dickkopf-related protein 3 is a potential A β -associated protein in Alzheimer's Disease. <i>Journal of Neurochemistry</i> , 2015, 134, 1152-1162.	3.9	31
130	Accumulation of the Amyloid- β Precursor Protein in Multivesicular Body-like Organelles. <i>Journal of Histochemistry and Cytochemistry</i> , 2002, 50, 681-690.	2.5	30
131	Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study. <i>Neurobiology of Aging</i> , 2015, 36, 2587-2596.	3.1	30
132	Mutations in the cyclic adenosine monophosphate response element of the tyrosine hydroxylase gene. <i>Annals of Neurology</i> , 2007, 62, 422-426.	5.3	29
133	Mechanisms of peripheral levodopa resistance in Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2022, 8, 56.	5.3	29
134	Rituximab and Intravenous Immunoglobulins for Relapsing Postinfectious Opsoclonus-Myoclonus Syndrome. <i>Pediatric Neurology</i> , 2008, 39, 213-217.	2.1	28
135	Plasma A β (Amyloid- β) Levels and Severity and Progression of Small Vessel Disease. <i>Stroke</i> , 2018, 49, 884-890.	2.0	27
136	Serum GFAP levels in optic neuropathies. <i>Journal of the Neurological Sciences</i> , 2012, 317, 117-122.	0.6	26
137	Mapping the multicausality of Alzheimer's disease through group model building. <i>GeroScience</i> , 2021, 43, 829-843.	4.6	26
138	Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. <i>Alzheimer's and Dementia</i> , 2022, 18, 1868-1879.	0.8	26
139	Inhibition of amyloid- β -induced cell death in human brain pericytes in vitro. <i>Brain Research</i> , 2002, 952, 111-121.	2.2	24
140	Aggregation and cytotoxic properties towards cultured cerebrovascular cells of Dutch-mutated A β ₄₀ (DA β ₂₁₋₄₀) are modulated by sulfate moieties of heparin. <i>Neuroscience Research</i> , 2010, 66, 380-389.	1.9	24
141	Two Greek siblings with sepiapterin reductase deficiency. <i>Molecular Genetics and Metabolism</i> , 2008, 94, 403-409.	1.1	23
142	Addition of MHPG to Alzheimer's disease biomarkers improves differentiation of dementia with Lewy bodies from Alzheimer's disease but not other dementias. <i>Alzheimer's and Dementia</i> , 2014, 10, 448.	0.8	23
143	A prediction model to calculate probability of Alzheimer's disease using cerebrospinal fluid biomarkers. <i>Alzheimer's and Dementia</i> , 2013, 9, 262-268.	0.8	22
144	An integrated multi-study analysis of intra-subject variability in cerebrospinal fluid amyloid- β concentrations collected by lumbar puncture and indwelling lumbar catheter. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 53.	6.2	22

#	ARTICLE	IF	CITATIONS
145	Mutations in <i>CYB561</i> Causing a Novel Orthostatic Hypotension Syndrome. <i>Circulation Research</i> , 2018, 122, 846-854.	4.5	22
146	Polyglutamine-Expanded Ataxin-3: A Target Engagement Marker for Spinocerebellar Ataxia Type 3 in Peripheral Blood. <i>Movement Disorders</i> , 2021, 36, 2675-2681.	3.9	22
147	Autoimmune Encephalitis Resembling Dementia Syndromes. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	6.0	22
148	Insights into the expanding phenotypic spectrum of inherited disorders of biogenic amines. <i>Nature Communications</i> , 2021, 12, 5529.	12.8	21
149	Serum GFAP differentiates Alzheimer's disease from frontotemporal dementia and predicts MCI-to-dementia conversion. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 659-667.	1.9	21
150	Sperm-Associated Antigen 16 Is a Novel Target of the Humoral Autoimmune Response in Multiple Sclerosis. <i>Journal of Immunology</i> , 2014, 193, 2147-2156.	0.8	20
151	A β 243 in human Alzheimer's disease: effects of active A β 242 immunization. <i>Acta Neuropathologica Communications</i> , 2019, 7, 141.	5.2	20
152	Hourly analysis of cerebrospinal fluid glucose shows large diurnal fluctuations. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2016, 36, 899-902.	4.3	19
153	3-Nitropropionic acid induces cell death and mitochondrial dysfunction in rat corticostriatal slice cultures. <i>Neuroscience Letters</i> , 2002, 329, 86-90.	2.1	18
154	CSF protein profiling using Multiplex Immuno-assay. <i>Journal of Neurology</i> , 2006, 253, 1177-1184.	3.6	18
155	Increased plasma amyloid- β 242 protein in sporadic inclusion body myositis. <i>Acta Neuropathologica</i> , 2009, 118, 429-431.	7.7	18
156	Child Neurology: Differential diagnosis of a low CSF glucose in children and young adults. <i>Neurology</i> , 2013, 81, e178-81.	1.1	18
157	Comparison of Different Matrices as Potential Quality Control Samples for Neurochemical Dementia Diagnostics. <i>Journal of Alzheimer's Disease</i> , 2016, 52, 51-64.	2.6	18
158	Validation of soluble amyloid- β precursor protein assays as diagnostic CSF biomarkers for neurodegenerative diseases. <i>Journal of Neurochemistry</i> , 2016, 137, 112-121.	3.9	17
159	Cerebrospinal fluid monocyte chemoattractant protein 1 correlates with progression of Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2020, 6, 21.	5.3	17
160	CSF levels of glutamine synthetase and GFAP to explore astrocytic damage in seronegative NMOSD. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 605-611.	1.9	17
161	Disturbed balance in the expression of MMP9 and TIMP3 in cerebral amyloid angiopathy-related intracerebral haemorrhage. <i>Acta Neuropathologica Communications</i> , 2020, 8, 99.	5.2	17
162	Off-label use of aducanumab for cerebral amyloid angiopathy. <i>Lancet Neurology</i> , The, 2021, 20, 596-597.	10.2	17

#	ARTICLE	IF	CITATIONS
163	Comparison of Methods for the Detection of Oligoclonal IgG Bands in Cerebrospinal Fluid and Serum: Results of the Dutch Quality Control Survey. <i>Clinical Chemistry</i> , 2002, 48, 1578-1580.	3.2	16
164	Detection of elevated levels of β -synuclein oligomers in CSF from patients with Parkinson disease. <i>Neurology</i> , 2011, 77, 510-511.	1.1	16
165	Total glutamine synthetase levels in cerebrospinal fluid of Alzheimer's disease patients are unchanged. <i>Neurobiology of Aging</i> , 2015, 36, 1271-1273.	3.1	16
166	White Matter Hyperintensities Potentiate Hippocampal Volume Reduction in Non-Demented Older Individuals with Abnormal Amyloid- β . <i>Journal of Alzheimer's Disease</i> , 2016, 55, 333-342.	2.6	16
167	Confirmation of neurometabolic diagnoses using age-dependent cerebrospinal fluid metabolomic profiles. <i>Journal of Inherited Metabolic Disease</i> , 2020, 43, 1112-1120.	3.6	16
168	Transient Induction of E-Selectin Expression Following TNF- α -Based Isolated Limb Perfusion in Melanoma and Sarcoma Patients Is Not Tumor Specific. <i>Journal of Immunotherapy</i> , 1996, 19, 33-44.	2.4	15
169	Upstream SLC2A1 translation initiation causes GLUT1 deficiency syndrome. <i>European Journal of Human Genetics</i> , 2017, 25, 771-774.	2.8	15
170	Neuropeptide changes and neuroactive amino acids in CSF from humans and sheep with neuronal ceroid lipofuscinoses (NCLs, Batten disease). <i>Neurochemistry International</i> , 2009, 55, 783-788.	3.8	14
171	Chitotriosidase as biomarker for early stage amyotrophic lateral sclerosis: a multicenter study. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2021, 22, 276-286.	1.7	14
172	Peripheral decarboxylase inhibitors paradoxically induce aromatic L-amino acid decarboxylase. <i>Npj Parkinson's Disease</i> , 2021, 7, 29.	5.3	14
173	Multiple Diagnostic Tests Are Needed to Assess Multiple Causes of Dementia. <i>Archives of Neurology</i> , 2006, 63, 144.	4.5	14
174	Amyloid β induces cellular relocalization and production of agrin and glypican-1. <i>Brain Research</i> , 2009, 1260, 38-46.	2.2	13
175	Do Amyloid β -associated Factors Co-deposit with $A\beta$ in Mouse Models for Alzheimer's Disease?. <i>Journal of Alzheimer's Disease</i> , 2010, 22, 345-355.	2.6	13
176	Identification of coronin-1a as a novel antibody target for clinically isolated syndrome and multiple sclerosis. <i>Journal of Neurochemistry</i> , 2013, 126, 483-492.	3.9	13
177	Clinical presentation and long-term follow-up of dopamine beta hydroxylase deficiency. <i>Journal of Inherited Metabolic Disease</i> , 2021, 44, 554-565.	3.6	13
178	Creatine protects against 3-nitropropionic acid-induced cell death in murine corticostriatal slice cultures. <i>Brain Research</i> , 2004, 1024, 16-24.	2.2	12
179	Amyloid beta-42 ($A\beta$ -42), neprilysin and cytokine levels. A pilot study in patients with HIV related cognitive impairments. <i>Journal of Neuroimmunology</i> , 2015, 282, 73-79.	2.3	12
180	Quantitative Genetics Validates Previous Genetic Variants and Identifies Novel Genetic Players Influencing Alzheimer's Disease Cerebrospinal Fluid Biomarkers. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 639-652.	2.6	12

#	ARTICLE	IF	CITATIONS
181	Physiologically based pharmacokinetic/pharmacodynamic model for the prediction of morphine brain disposition and analgesia in adults and children. <i>PLoS Computational Biology</i> , 2021, 17, e1008786.	3.2	12
182	Hypoglycorrhachia: A simple clue, simply missed. <i>Annals of Neurology</i> , 2001, 49, 685-686.	5.3	11
183	CSF α -synuclein concentrations do not fluctuate over hours and are not correlated to amyloid β in humans. <i>Neuroscience Letters</i> , 2011, 504, 336-338.	2.1	11
184	The Paradox of Hyperdopaminuria in Aromatic L-Amino Acid Deficiency Explained. <i>JIMD Reports</i> , 2011, 4, 39-45.	1.5	11
185	Diagnosis of progressive supranuclear palsy: can measurement of tau forms help?. <i>Neurobiology of Aging</i> , 2012, 33, 204.e17-204.e18.	3.1	11
186	Novel cerebrospinal fluid and serum autoantibody targets for clinically isolated syndrome. <i>Journal of Neurochemistry</i> , 2012, 123, 568-577.	3.9	11
187	Replicated Evidence of Absence of Association between Serum S100B and (Risk of) Psychotic Disorder. <i>PLoS ONE</i> , 2013, 8, e82535.	2.5	11
188	Serum angiogenin levels are elevated in ALS, but not Parkinson's disease: Table A1. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 1439-1440.	1.9	11
189	Cerebral Level of vGlut1 is Increased and Level of Glycine is Decreased in TgSwDI Mice. <i>Journal of Alzheimer's Disease</i> , 2014, 39, 89-101.	2.6	11
190	Human type 1 and type 2 conventional dendritic cells express indoleamine 2,3-dioxygenase 1 with functional effects on T cell priming. <i>European Journal of Immunology</i> , 2021, 51, 1494-1504.	2.9	11
191	MFG-E8 (LACTADHERIN): a novel marker associated with cerebral amyloid angiopathy. <i>Acta Neuropathologica Communications</i> , 2021, 9, 154.	5.2	11
192	Identification of cerebrospinal fluid biomarkers for parkinsonism using a proteomics approach. <i>Npj Parkinson's Disease</i> , 2021, 7, 107.	5.3	11
193	Absence of heparan sulfate proteoglycans in Lewy bodies and Lewy neurites in Parkinson's disease brains. <i>Journal of Alzheimer's Disease</i> , 2004, 6, 469-474.	2.6	10
194	CSF hypocretin-1 levels are normal in patients with amyotrophic lateral sclerosis. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 2009, 10, 487-489.	2.1	10
195	A rational design to create hybrid β -sheet breaker peptides to inhibit aggregation and toxicity of amyloid- β . <i>MedChemComm</i> , 2011, 2, 60-64.	3.4	10
196	Detection of tau forms in CSF requires sensitive techniques. <i>Neurobiology of Aging</i> , 2012, 33, 1841.	3.1	10
197	Levels of HVA, 5-HIAA, and MHPC in the CSF of vascular parkinsonism compared to Parkinson's disease and controls. <i>Journal of Neurology</i> , 2013, 260, 3129-3133.	3.6	10
198	Aromatic L-Amino acid decarboxylase deficiency: A new case from Turkey with a novel mutation. <i>Annals of Indian Academy of Neurology</i> , 2014, 17, 234.	0.5	10

#	ARTICLE	IF	CITATIONS
199	Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 543-555.	2.6	10
200	Multicenter Analytical Validation of A β 40 Immunoassays. <i>Frontiers in Neurology</i> , 2017, 8, 310.	2.4	10
201	CSF A β -synuclein correlates with CSF neurogranin in late-life depression. <i>International Journal of Neuroscience</i> , 2021, 131, 357-361.	1.6	10
202	The Diagnostic Value of CSF Amyloid- β 43 in Differentiation of Dementia Syndromes. <i>Current Alzheimer Research</i> , 2013, 10, 1034-1040.	1.4	10
203	Cerebrospinal fluid tau levels in frontotemporal dementia. <i>Annals of Neurology</i> , 2005, 58, 656-657.	5.3	9
204	TDP-43 plasma levels do not differentiate sporadic inclusion body myositis from other inflammatory myopathies. <i>Acta Neuropathologica</i> , 2010, 120, 825-826.	7.7	9
205	Tau forms in CSF as a reliable biomarker for progressive supranuclear palsy. <i>Neurology</i> , 2011, 76, 1443-1443.	1.1	9
206	Soluble TLR2 and 4 concentrations in cerebrospinal fluid in HIV/SIV-related neuropathological conditions. <i>Journal of NeuroVirology</i> , 2017, 23, 250-259.	2.1	9
207	Sleep-Cognition Hypothesis In maritime Pilots, what is the effect of long-term work-related poor sleep on cognition and amyloid accumulation in healthy middle-aged maritime pilots: methodology of a case-control study. <i>BMJ Open</i> , 2019, 9, e026992.	1.9	9
208	Cerebrospinal fluid myelin basic protein is elevated in multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , 2020, 76, 80-84.	2.2	8
209	Antisense Oligonucleotide-Induced Amyloid Precursor Protein Splicing Modulation as a Therapeutic Approach for Dutch-Type Cerebral Amyloid Angiopathy. <i>Nucleic Acid Therapeutics</i> , 2021, 31, 351-363.	3.6	8
210	The novel P330L pathogenic variant of aromatic amino acid decarboxylase maps on the catalytic flexible loop underlying its crucial role. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, 305.	5.4	8
211	Cerebral Amyloid Angiopathy with Severe Secondary Vascular Pathology: A Histopathological Study. <i>Dementia and Geriatric Cognitive Disorders</i> , 2005, 20, 321-330.	1.5	7
212	CSF Studies Facilitate DNA Diagnosis in Familial Alzheimer's Disease Due to a Presenilin-1 Mutation. <i>Journal of Alzheimer's Disease</i> , 2009, 17, 53-57.	2.6	7
213	Linkage analysis for plasma amyloid beta levels in persons with hypertension implicates A β -40 levels to presenilin 2. <i>Human Genetics</i> , 2012, 131, 1869-1876.	3.8	7
214	Parkinson's Disease Diagnostic Observations (PADDO): study rationale and design of a prospective cohort study for early differentiation of parkinsonism. <i>BMC Neurology</i> , 2018, 18, 69.	1.8	7
215	Cerebrospinal Fluid Galectin-1 Levels Discriminate Patients with Parkinsonism from Controls. <i>Molecular Neurobiology</i> , 2019, 56, 5067-5074.	4.0	7
216	Novel Protein Biomarkers of Monoamine Metabolism Defects Correlate with Disease Severity. <i>Movement Disorders</i> , 2021, 36, 690-703.	3.9	7

#	ARTICLE	IF	CITATIONS
217	Neurofilament light chain: A novel blood biomarker in patients with ataxia telangiectasia. <i>European Journal of Paediatric Neurology</i> , 2021, 32, 93-97.	1.6	7
218	Concordance of <sc>CSF RTâ€œQuIC</sc> across the European <sc>Creutzfeldtâ€œJakob</sc> Disease surveillance network. <i>European Journal of Neurology</i> , 2022, , .	3.3	7
219	The sex difference of plasma homovanillic acid is unaffected by cross-sex hormone administration in transsexual subjects. <i>Journal of Endocrinology</i> , 2005, 187, 109-116.	2.6	6
220	Alzheimer Biomarkers and Clinical Alzheimer Disease were Not Associated with Increased Cerebrovascular Disease in a Memory Clinic Population. <i>Current Alzheimer Research</i> , 2014, 11, 40-46.	1.4	6
221	Saffold cardiovirus and multiple sclerosis: no evidence for an association. <i>Annals of Clinical and Translational Neurology</i> , 2014, 1, 618-621.	3.7	6
222	Valuing biomarker diagnostics for dementia care: enhancing the reflection of patients, their care-givers and members of the wider public. <i>Medicine, Health Care and Philosophy</i> , 2019, 22, 439-451.	1.8	6
223	Reduced Influence of apoE on AÎ²43 Aggregation and Reduced Vascular AÎ²43 Toxicity as Compared with AÎ²40 and AÎ²42. <i>Molecular Neurobiology</i> , 2020, 57, 2131-2141.	4.0	6
224	Normal cerebrospinal fluid concentrations of PDGFRÎ² in patients with cerebral amyloid angiopathy and Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2022, 18, 1788-1796.	0.8	6
225	Cerebrospinal Fluid Biomarkers in the Evaluation of Alzheimer Disease. <i>Clinical Chemistry</i> , 2008, 54, 1589-1591.	3.2	5
226	Biomarkers in cerebrospinal fluid for synucleinopathies, tauopathies, and other neurodegenerative disorders. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2018, 146, 99-113.	1.8	5
227	White Matter Hyperintensities Are No Major Confounder for Alzheimerâ€™s Disease Cerebrospinal Fluid Biomarkers. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 163-175.	2.6	5
228	Cerebrospinal fluid levels of the neurotrophic factor neuroleukin are increased in early Alzheimerâ€™s disease, but not in cerebral amyloid angiopathy. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 160.	6.2	5
229	Chronic Herpes Simplex Virus Encephalitis in Childhood. <i>Pediatric Neurology</i> , 2006, 35, 57-61.	2.1	4
230	Cerebrospinal Fluid Tau and Amyloid Î² Proteins Do Not Correlate With Cognitive Functioning in Cognitively Impaired Memory Clinic Patients. <i>CNS Spectrums</i> , 2010, 15, 588-593.	1.2	4
231	Diagnostic challenges in parkinsonism. <i>Expert Review of Neurotherapeutics</i> , 2011, 11, 1099-1101.	2.8	4
232	Optimisation of the quantification of glutamine synthetase and myelin basic protein in cerebrospinal fluid by a combined acidification and neutralisation protocol. <i>Journal of Immunological Methods</i> , 2012, 381, 1-8.	1.4	4
233	Cerebrospinal Fluid NrcAM is not a Suitable Biomarker to Discriminate between Dementia Disorders â€œ A Pilot Study. <i>Journal of Alzheimer's Disease</i> , 2015, 46, 605-609.	2.6	4
234	Proteomic profiling of striatal tissue of a rat model of Parkinson's disease after implantation of collagenâ€œencapsulated human umbilical cord mesenchymal stem cells. <i>Journal of Tissue Engineering and Regenerative Medicine</i> , 2020, 14, 1077-1086.	2.7	4

#	ARTICLE	IF	CITATIONS
235	Degeneration of Human Cerebrovascular Smooth Muscle Cells and Pericytes Caused by Amyloid β^2 Protein. , 2000, , 265-279.		4
236	Factors associated with mortality in early stages of parkinsonism. Npj Parkinson's Disease, 2022, 8, .	5.3	4
237	Cerebrospinal Fluid Biomarkers in Diagnosing Alzheimer's Disease in Clinical Practice: An Illustration with 3 Case Reports. Case Reports in Neurology, 2010, 2, 5-11.	0.7	3
238	Blood, urine and cerebrospinal fluid analysis in TH and AADC deficiency and the effect of treatment. Molecular Genetics and Metabolism Reports, 2021, 27, 100762.	1.1	3
239	Phase II trial of natalizumab for the treatment of anti-Hu associated paraneoplastic neurological syndromes. Neuro-Oncology Advances, 2021, 3, vdab145.	0.7	3
240	P3-045 Tau protein phosphorylated at threonine 181 in cerebrospinal fluid as a possible biomarker for Alzheimer's disease. Neurobiology of Aging, 2004, 25, S364.	3.1	2
241	Analytical performance of a kinetic method for the determination of lactate dehydrogenase catalytic concentration in cerebrospinal fluid. Clinica Chimica Acta, 2004, 346, 221-223.	1.1	2
242	A multifunctional ELISA to measure oxidised proteins: oxPin1 in Alzheimer's brain as an example. BBA Clinical, 2015, 4, 1-6.	4.1	2
243	Serum S100B: A proxy marker for grey and white matter status in the absence and presence of (increased risk of) psychotic disorder?. PLoS ONE, 2017, 12, e0174752.	2.5	2
244	Prevalence of sporadic cerebral amyloid angiopathy: A systematic review and meta-analysis. Alzheimer's and Dementia, 2021, 17, .	0.8	2
245	Amyloid β^2 eta peptides in CSF and plasma discriminate cerebral amyloid angiopathy from controls. Alzheimer's and Dementia, 2021, 17, .	0.8	2
246	Inhibition of Neuroinflammation May Mediate the Disease-Modifying Effects of Exercise: Implications for Parkinson's Disease. Journal of Parkinson's Disease, 2022, 12, 1419-1422.	2.8	2
247	POTENTIAL PITFALLS IN THE ANALYSIS OF CSF BIOMARKERS IN ALZHEIMER'S DISEASE AND VASCULAR DEMENTIA. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2007, 62, 924-925.	3.6	1
248	CEREBROSPINAL FLUID BIOMARKERS IN ALZHEIMER'S DISEASE: ARE THE HYPOTHESES MORE DYNAMIC THAN THE BIOMARKERS?. Journal of the American Geriatrics Society, 2010, 58, 1619-1620.	2.6	1
249	P3-246: α -SYN, PLASMA AMYLOID BETA LEVELS AND MRI MARKERS: THE ROTTERDAM STUDY. Alzheimer's and Dementia, 2018, 14, P1166.	0.8	1
250	International initiative for harmonization of cerebrospinal fluid diagnostic comments in Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e047209.	0.8	1
251	Hypoglycorrhachia: A simple clue, simply missed. Annals of Neurology, 2001, 49, 685-686.	5.3	1
252	Amyloid Formation in Senile Plaques and Congophilic Angiopathy. Journal of Neuropathology and Experimental Neurology, 1998, 57, 97-98.	1.7	0

#	ARTICLE	IF	CITATIONS
253	P3-167 Specific association of small heat shock proteins with the pathological features of Alzheimer's and Parkinson's disease brains. <i>Neurobiology of Aging</i> , 2004, 25, S403.	3.1	0
254	P1-178 Small heat shock proteins affect amyloid- β^2 protein aggregation and inhibit cerebrovascular amyloid- β^2 protein toxicity. <i>Neurobiology of Aging</i> , 2004, 25, S146.	3.1	0
255	The accuracy of the arginine growth hormone test in Parkinsonism. <i>Movement Disorders</i> , 2008, 23, 1330-1330.	3.9	0
256	The use of indexes in the interpretation of cerebrospinal fluid analyses. <i>Neurobiology of Aging</i> , 2010, 31, 1654.	3.1	0
257	Taking a closer look at Spag16 in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2014, 275, 14.	2.3	0
258	Decreased miR-219 expression in MS: Clinical implications?. <i>Journal of Neuroimmunology</i> , 2014, 275, 111.	2.3	0
259	P1-124: BINDING OF THE AB43 PEPTIDE TO APOLIPOPROTEIN E AND ITS ROLE IN CLEARANCE. , 2014, 10, P346-P346.		0
260	P2-117: MICRO-RNAS AS NOVEL BIOMARKERS IN AD: DIFFERENTIAL EXPRESSION IN HIPPOCAMPUS AND IN CELL-FREE CEREBROSPINAL FLUID. , 2014, 10, P514-P514.		0
261	P2-051: THE HCMEC/D3 CELL LINE IS NOT SUITABLE AS A MODEL FOR A β^2 TRANSPORT BY THE HUMAN BLOOD-BRAIN BARRIER. , 2014, 10, P489-P489.		0
262	P4-270: CORRELATIONS OF CSF BIOMARKER LEVELS WITH LATERAL VENTRICULAR CSF VOLUMES. , 2014, 10, P883-P883.		0
263	P4-229: Improved CSF-based discrimination between Alzheimer's disease patients and controls after correction for ventricular volumes. , 2015, 11, P868-P868.		0
264	P1-120: Standardization of a method for diagnostic biomarker validation for neurodegenerative diseases: App assays as example. , 2015, 11, P387-P387.		0
265	IC-P-089: Vascular and amyloid pathologies in memory clinic patients: Synergetic or independent?. , 2015, 11, P62-P62.		0
266	P4-100: Vascular and amyloid pathologies in memory clinic patients: Synergetic or independent?. , 2015, 11, P814-P814.		0
267	[O2â€™04â€™06]: ASSOCIATION BETWEEN NOCTURNAL AMYLOID BETA FLUCTUATIONS AND SLEEP. <i>Alzheimer's and Dementia</i> , 2017, 13, P559.	0.8	0
268	[P4â€™394]: ASSOCIATIONS OF PLASMA AMYLOID BETA LEVELS WITH SEVERITY AND PROGRESSION OF CEREBRAL SMALL VESSEL DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P1479.	0.8	0
269	P3â€™232: THE ASSOCIATION BETWEEN BLOODâ€™BRAINâ€™BARRIER DYSFUNCTION AND CSF Pâ€™TAU IS MEDIATED BY BETAâ€™AMYLOID IN THE PRESENCE OF ELEVATED ILâ€™6. <i>Alzheimer's and Dementia</i> , 2018, 14, P1160.	0.8	0
270	O3â€™09â€™04: PLASMA AMYLOID β^2 LEVELS, CEREBRAL ATROPHY AND DEMENTIA RISK: THE ROTTERDAM STUDY. <i>Alzheimer's and Dementia</i> , 2018, 14, P1037.	0.8	0

#	ARTICLE	IF	CITATIONS
271	Reader response: Blood NfL: A biomarker for disease severity and progression in Parkinson disease. <i>Neurology</i> , 2020, 95, 657.2-658.	1.1	0
272	Metabolomics biomarker discovery in cerebrospinal fluid for cerebral amyloid angiopathy. <i>Alzheimer's and Dementia</i> , 2020, 16, e041934.	0.8	0
273	Urokinase plasminogen activator (uPA) as a novel biomarker for cerebral amyloid angiopathy. <i>Alzheimer's and Dementia</i> , 2020, 16, e042512.	0.8	0
274	Neuroleukin: A potential cerebrospinal fluid biomarker for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e042741.	0.8	0
275	Platelet-derived growth factor receptor-beta as a potential CSF biomarker for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e042924.	0.8	0
276	Elevated expression of urokinase plasminogen activator in rodent models and patients with cerebral amyloid angiopathy. <i>Neuropathology and Applied Neurobiology</i> , 2022, 48, e12804.	3.2	0
277	Views on the Desirability of Diagnosing Sporadic Cerebral Amyloid Angiopathy with Biological Evidence. <i>Journal of Alzheimer's Disease</i> , 2022, , 1-10.	2.6	0
278	Urokinase plasminogen activator (uPA) as a novel biomarker for cerebral amyloid angiopathy. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0